Abstract:Introduction: Xenograft models of epithelial malignancies potentially have greater correlation with clinical end points. We implanted 153 primary non-small cell lung carcinomas into non-obese diabetic-severe combined immunodeficient mice to develop primary lung cancer xenografts. Sixty-three xenografts formed. However, in 19 implantations, tumors consisted of a lymphocyte proliferation without a carcinoma component. We further characterized these lymphomas to determine clinicopathological features associated with their formation. Methods: Lymphomas were investigated morphologically and by silver in situ hybridization to determine their species of origin. Characterization both of the xenograft lymphomas and the primary NSCLCs from which they were derived included immunohistochemistry for lymphoma markers and Epstein Barr virus Early RNA (EBER) by in situ hybridization. DNA was profiled using the MassARRAY platform; EML4-ALK translocations and lymphocyte infiltration were assessed in the primary tumor. Lymphoma formation was correlated with patient and primary tumor characteristics and survival. Results: The lymphocytic tumors were EBER positive, human diffuse large B-cell lymphomas (DLBCLs). Significantly more DLBCLs that formed in mice arose in primary lung adenocarcinomas and in epithelial growth factor receptor mutant never smokers. DLBCL formation was not associated with the degree of tumor-infiltrating lymphocytes or EBER-positive lymphocytes in the primary NSCLCs. Patients whose tumors developed DLBCL had longer disease-free survival compared with patients whose tumors formed epithelial xenografts (hazard ratio: 0.44; 95% confidence interval: 0.18 -1.06, Wald p = 0.07), regardless of genotype. Conclusion: We hypothesize that mechanisms involved in the active suppression of viral antigens may also be involved in the suppression of tumor antigens, and may have resulted in the observed favorable clinical outcome.

Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response

Natural Killer Cells: Tumor Surveillance and Signaling

Tumor growth impedes natural-killer-cell maturation in the bone marrow.

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation

Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer

Natural Killer Cell Behavior in Lymph Nodes Revealed by Static and Real-Time Imaging

Endogenous mouse mammary tumor viruses influence the development of thymic αβ NKT cells and innate CD8+ T cells (111.26)

Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells

Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

Influence of Natural Killer Cells and Perforin-Mediated Cytolysis on the Development of Chemically Induced Lung Cancer in A/J Mice

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Cancer immunity by tissue‐resident type 1 innate lymphoid cells and killer innate‐like T cells

NK-cell Activation by LIGHT Triggers Tumor-Specific CD8+ T-cell Immunity to Reject Established Tumors.

Ablation of NK Cell Function During Tumor Growth Favors Type 2-Associated Macrophages, Leading to Suppressed CTL Generation

CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy

The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.

Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases